Background
Breast cancer (BC) is a common cancer in women worldwide [
1]. Although earlier diagnosis and improvements in treatment have reduced the mortality rate of BC, the incidence of BC is estimated to be increasing globally [
1]. Thus, prevention and treatment of BC remain a major public health concern. BC subtypes, such as inflammatory breast cancer (IBC) and triple negative breast cancer (TNBC), are aggressive types of BC, which are extremely lethal and have higher potential for distant metastasis [
2,
3]. Majority of BC patients succumb to metastasis. Thus, understanding the characteristics of the sub-population of cancer cells that exhibit the invasive phenotype is fundamental for discovering novel targets to block the invasion-metastasis cascade and ensure improved BC treatment.
Cancer cells adopt various strategies that allow them to be more aggressive such as changing their cellular metabolism [
4]. Metabolic reprogramming is increasingly being recognized as a fundamental hallmark of cancer, and efforts to identify drugs that can target cancer metabolism are underway [
5]. Several studies have revealed that oncogenes make cells more glycolytic [
6,
7], and in fact, many tumor cells consume glucose and produce lactate at significantly higher rates than the surrounding tissue, even when enough oxygen exists [
8,
9]. 2-deoxy-D-glucose (2-DG), a D-glucose mimetic, inhibits glycolysis due to formation and intracellular accumulation of 2-deoxy-D-glucose-6-phosphate, inhibiting the function of hexokinase and glucose-6-phosphate isomerase [
10,
11]. 2-DG has a potential application as an adjuvant for improving cancer therapy, as it was to be able to reduce cancer cell viability [
12‐
15] and has also been assessed in several clinical studies as an anticancer agent [
16‐
18]. However, clinical use of 2-DG still has been carefully studied because of its side effects [
11,
14]. Thus, combination of lower dose of 2-DG with other anticancer drugs, or with radiotherapy, is promising for clinical use [
11]. A recent report showed that 2-DG is also effective in inhibiting migration and invasion ability of an invasive subclone of the TNBC cell line, Hs578T [
19]. Due to limited therapeutic options for targeting metastasis, use of 2-DG for blocking cancer invasiveness is attractive. However, the study only showed the result of one BC cell line, Hs578T, and thus, further studies are required to clarify the role of glycolysis in BC invasion.
It was originally hypothesized that cancer cells utilize aerobic glycolysis because of mitochondrial respiratory dysfunction [
20]. However, later evidence suggested that most tumor cells have functional tricarboxylic acid (TCA) cycle and electron transport chain (ETC), despite which, cancer cells favor the use of glucose to produce lactate rather than acetyl-CoA for TCA cycle [
4,
20,
21]. Glutamine can be a primary source of citrate via reductive metabolism and is known to be used as a source of TCA metabolites in aggressive cancers [
22,
23]. In addition, several reports have revealed that mitochondria, the site of TCA cycle and ETC, is an important organelle that destines a cell to a metastatic phenotype [
24,
25]. Thus, it is still controversial which metabolic arm i.e., glycolysis or, TCA and ETC is significant for maintaining the invasive potential in BC.
Herein, we establish that BC invasive cells (INV) collected from transwell inserts is a discernible population with a persistent phenotype that are hyperinvasive. These cells showed upregulation of glucose uptake and were effectively targeted using 2-DG. This effectiveness of 2-DG on blocking invasion was observed in several aggressive BC cell lines, SUM149 (IBC), MDA-MB-231 (TNBC), and HCC1937 (BRCA1mut/TNBC), and of note, low dose of 2-DG (1 mM), non-toxic to MDA-MB-231 and HCC1937 viability, was effective in reducing their invasion. In contrast, blocking function of TCA cycle and ETC had no significant effect on their invasiveness, although levels of TCA metabolites or detection of mitochondrial membrane potential with JC-1 staining indicated that INV cells originally had functional TCA cycles and membrane potentials. Overall, our results convincingly establish that inhibition of glycolysis, such as with low dose of 2-DG, is a viable therapeutic option to blocking aggressive BC invasiveness.
Methods
Cell culture and reagents
Human BC cell lines, MCF-7 (ATCC® HTB-22), BT-474 (ATCC® HTB-20), SK-BR-3 (ATCC® HTB-30), MDA-MB-468 (ATCC® HTB-132), MDA-MB-231 (ATCC® HTB-26), HCC1937 (ATCC® CRL-2336) derived from different breast cancer subtypes were purchased from ATCC (Manassas, VA, USA), and SUM149 (Asterand SUM-149PT) from Asterand (Hertfordshire, UK) in 2013.The cell lines were authenticated by provider with morphology, karyotyping, and PCR based approaches. The subtypes of each cell lines were further authenticated with determining ER, PgR and HER2 expression in a recent paper [
26]. Cells were cultured in complete RPMI (Roswell Park Memorial Institute) medium (Nakalai, Kyoto-shi, Kyoto-fu, Japan) consisting of 10% fetal bovine serum (FBS, HyClone Laboratories, GE Healthcare, Logan, UT, USA), 2 mM L-glutamine, and 100 U/ml penicillin/streptomycin (Gibco, Gaithersburg, MD, USA) at 37 °C and 5% CO
2. Cells in logarithmic growth phase were seeded at an appropriate density, and used for all experiments. 2-deoxy-D-glucose (2-DG) (Sigma-Aldrich, St. Louis, MO, USA), 3-Nitropropionic Acid (3-NA) (Cayman Chemical, Ann Arbor, MI, USA), CB-839 (Cayman Chemical), Phloretin (Tokyo Chemical Industry, Nihonbashi, Tokyo, Japan) were the inhibitors used in this study.
Transwell invasion assay
The invasive potential of seven BC cell lines were examined as previously described [
27‐
29]. The transwell membrane was photographed under bright field using a BZ-9000 fluorescence microscope (Keyence, Osaka, Japan) using a Nikon Plan Apo 4x/0.2 lens. Numbers of invaded cells in each field were counted with the particle counting application of ImageJ software (Version 1.52q) [
27].
For inhibitor studies, cells were pre-treated with 2-DG, 3-NA, or CB-839 for 16 h, trypsinized, suspended in serum-free RPMI with appropriate inhibitor, and then used for the invasion assay. Inhibitor was also added to the lower well, and the invasion assay was performed for 24 h. In addition, surviving fraction of cells treated with each inhibitor for 16 h was examined by counting viable cells using trypan blue staining.
INV preparation and re-invasion assay
To prepare the invaded cells of SUM149 (INV), transwell invasion assays were performed as described previously [
28,
29]. For the re-invasion assay, WCC and INV were both cultured for 1, 4, 7, 12, or 19 days, and the transwell invasion assay was performed repeatedly with these cells as described previously [
29].
INV and WCC (1 × 10^5 cells/sample for INV, and 1 × 10^6 cells/sample for WCC, respectively) were used for the extraction of intracellular metabolites [
28], and the metabolome analysis was performed with CE-TOFMS as described earlier [
28,
30‐
32]. The collection methods of INV and WCC for the metabolome analysis were summarized in reference [
28]. Analysis of raw data measured by CE-TOFMS was performed as described previously [
28,
33].
Immunoblotting
Immunoblotting was performed as described previously [
34]. Briefly, cells were lysed in 2× Laemmli sample buffer, followed by electrophoresis using the Novex® NuPAGE® SDS-PAGE Gel system (ThermoFisher Scientific, Waltham, MA, USA). Primary antibodies against Pyruvate Dehydrogenase E1-alpha subunit (9H9AF5) (PDH), phosphorylated-Pyruvate Dehydrogenase E1-alpha subunit Ser300 (pPDH S300), Ser232 (pPDH S232), or Ser239 (pPDH S239) (Abcam, Cambridge, UK) were used along with horseradish peroxidase-conjugated anti-mouse IgG or anti-rabbit IgG (Amersham Biosciences; Buckinghamshire, UK). Bands were detected by enhanced chemiluminescence and visualized with a Lumino image analyzer, LAS 4000 (Fujifilm, Tokyo, Japan) using the ImageQuant LAS 4000 Control Software.
Flow cytometry
In order to examine the glucose uptake into living cells, 2-NBDG (2-Deoxy-2-[(7-nitro-2,1,3-benzoxadiazol-4-yl)amino]-D-glucose, Cayman Chemical), a fluorescent derivative of glucose, was used. For WCC, cells were separately cultured as 3 groups; control, 2-NBDG treating, or 2-NBDG + Phloretin (inhibitor for the glucose transporter) treating groups. On the day of flow cytometry experiment, cells were washed with PBS and medium were changed to fresh RPMI supplemented with 0.5% FBS with or without 100 μM Phloretin. After 4 h incubation, 60 μM 2-NBDG was added to 2-NBDG group, and 2-NBDG + Phloretin group, and were incubated another 1 h. Cells were then washed with PBS, incubated with Accutase for 15 min (Innovative Cell Technologies Inc.), collected and used for flow cytometry analysis in accordance with the manufacturer’s instructions (CytoFLEX S with Analysis Software; Beckman Coulter). For INV, invasion assay was performed 1 day before the flow cytometry experiment. After 24 h INV cells underneath the transwell were directly treated with 2-NBDG or 2-NBDG + Phloretin. WCC were also subjected to same treatment groups. Cells were collected with Accutase for 15 min and used for the flow cytometry analysis.
Immunofluorescence study and image acquisition
Immunofluorescence study, and image acquisition were performed with some modifications from previous studies [
27]. Briefly, cells were cultured on glass slide chamber with phenol red free RPMI at appropriate density. On the day of immunofluorescence experiment, cells were washed with PBS, and medium was changed to fresh phenol red free RPMI with or without 3-NA. After 5 h incubation at 37 °C/5% CO
2, 5, 5′, 6, 6′-tetrachloro-1, 1′, tetraethylbenzimidazolocarbocyanine iodide (JC-1, mitochondrial membrane potential detection indicator, ThermoFisher Scientific) and NucBlue® Live ReadyProbes (Nuclear staining solution, ThermoFisher Scientific) were added to each well, and incubated for 30 min. Cells were washed with PBS and fresh phenol red free RPMI was added, and images were acquired using a BZ-9000 fluorescence microscope (Keyence, Osaka, Japan) using a 10X PlanFluor NA 0.30 Ph1 lens with BZ filters for TRITC, GFP-B, and DAPI. Images were uniformly processed in Creative Cloud Photoshop CC using the brightness and contrast tools.
Lactate measurement
Cells were separately cultured as 3 groups; control, 0.3 mM 2-DG treatment, or 1 mM 2-DG treatment groups. On the day before the experiment, cells were washed with PBS and medium was changed to fresh RPMI with appropriate concentration of 2-DG. After 16 h incubation, conditioned medium was collected and used for the assay according to the manufacture’s protocol (Lactate Assay Kit-WST, Dojindo).
Spheroid invasion assay
Spheroid invasion assay was performed in ultra-low attachment multiple 96 well plates (Sigma-Aldrich) [
28,
29]. Cells (5 × 10^3) were plated in each well and incubated in 37 °C CO
2 incubator. After 48 h, spheroids were stained with JC-1 (1:50 concentration) for 30 min, embedded into phenol red-free collagen solution (custom version 3D Ready Atelocollagen, KOKEN CO., LTD., Bunkyo-ku, Tokyo, Japan), followed by 1 h incubation at 37 °C/5% CO
2 to allow solidification of collagen solution. Image of spheroid was captured at 1 h and 24 h after embedding into collagen gel and fluorescence was detected and photographed with a BZ-9000 fluorescence microscope using a 4X PlanApo λ NA 0.20 lends with BZ filters for TRITC, GFP-B (Keyence, Osaka, Japan). Representative images were uniformly processed in Adobe Photoshop using the brightness and contrast tools.
Statistical analysis
All results are shown as the mean +/− SD. Significance was analyzed using unpaired Student’s t-test. P value < 0.05 was considered significant.
Discussion
Most cancer cells rely on glycolysis even when oxygen is available, a phenomenon known as the Warburg effect [
42]. Aggressive type of BC, viz. IBC and TNBC, have been shown to possess higher levels of glycolytic activity than ER+ breast cancer cells [
43‐
46], however, the role of glycolysis specifically on their invasiveness is still unclear. In this study, we establish that INV from an IBC cell line had a persistently hyper-invasive phenotype. Such INV showed upregulation of glucose uptake, and were effectively targeted using a glycolysis inhibitor, 2-DG. Several earlier studies have shown the ability of 2-DG to block cancer growth [
11‐
15,
47]. However, many of the clinical trials using 2-DG were discontinued due to the adverse side effects caused by the high doses of 2-DG [
11,
18]. Importantly, the concentration of 2-DG that we used in this study, 1 mM, is five times lower than the doses used in recent studies focusing on blocking cancer cell growth (≥5 mM) [
39‐
41], and 1 mM was shown as non-toxic on cell survival [
41]. In accordance, we observed that 1 mM of 2-DG did not reduce cell survival of MDA-MB-231 and HCC1937 cell lines, but of note, it was significantly effective in blocking their invasion. Sadhbh O’Neill et al have reported that 2-DG is effective to inhibit migration and invasion ability of invasive BC subclone, Hs578T, but they used much higher concentration of 2-DG i.e., 15 mM (15 times the dose used in the current study), and have not focused on the effect of 2-DG with lower dose [
19]. The associated side effects of such a high dose of 2-DG would impede its use in clinical trials. However, lower doses of 2-DG which can still block cancer invasiveness, as we have shown here in aggressive BC cell lines, could be effectively applied as adjuvants to other anti-cancer therapies.
Several reports have shown that cancer cells have functional TCA cycle and ETC [
4,
20,
21], concordantly, we observed that invading cells that move outward from spheroids embedded in collagen gel exhibited high mitochondrial membrane potential, suggesting that they possessed functional ETC. Blocking TCA and ETC with pharmacological inhibitor treatment diminished mitochondrial membrane potential, but it had no significant effects on blocking their invasion, indicating that TCA and ETC were less important than glycolysis to drive BC invasiveness. Glutamine can be a primary source fueling the TCA cycle [
22,
23]. A recent study has shown that GLS inhibitor was effective in diminishing cell growth by limiting influx of glutamine derivatives into the TCA cycle, but this effect was only detected in the cells which have high levels of GLS, suggesting that the role of glutamine for TCA cycle is cell line-specific [
48]. In this study, we used glutamine free media or GLS1 inhibitor (CB-839) to investigate the role of glutamine-TCA cycle pathway in SUM149. However, the no significant change was observed on their invasiveness. As expected from this data and previous literature, expression of GLS was low in SUM149 cells compared to other BC cells (data not shown) hence, inhibition of GLS1 had no effect in these cells. Also, the INV cells produce higher levels of all non-essential amino acids compared to WCC cells (Supplemental Figure
4) and could potentially fuel TCA through anaplerosis even in the absence of glutamine in the media [
49].
Several studies have revealed that metformin is effective in blocking growth of aggressive cancer, including TNBC [
50,
51]. Metformin has been used to treat type II diabetes, and its function is the inhibition of mitochondrial membrane complex I [
51]. Blocking of mitochondrial membrane complex I decreases proton-driven synthesis of ATP, causing cellular energetic stress and activation of AMPK, which in turn impairs cell proliferation [
51]. Thus, mitochondrial respiration system may be important for the cancer cell growth, rather than for the invasiveness. In addition, it is well known that many of the amino acids are synthesized from TCA cycle intermediates [
49], which were important source for cell living or may be for invasion. In this study, we found that most of the amino acid levels were significantly increased in INV compared to WCC (Supplemental Figure
4). Inhibiting mitochondrial respiration complex II with 0.75 mM or 1.5 mM 3-NA for 16 h did not reduce survival of SUM149, MDA-MB-231, and HCC1937 in this study. However, in the case of MDA-MB-468, the least aggressive of the three TNBC cell lines, interestingly, treatment with the same doses of 3-NA, for 16 h drastically diminished cell growth and we were unable to collect the cells to use for the further invasion assay (data not shown). Thus, mitochondrial respiration system or TCA cycle may have significant role in cancer growth on certain cell types. The role of TCA cycle or ETC in SUM149, MDA-MB-231, and HCC1937 will be further delineated in future studies. However, it is now clear that although the TCA is not critical to the invasive process, they also have an active TCA cycle (through anaplerosis) which provides for cellular energy needs for sustenance, while glycolysis caters to the need for fast energy production required for invasion to occur within the nutrient deprived tumor conditions.
Epithelial mesenchymal transition (EMT) confers metastatic properties to cancer cells by increasing mobility, invasion, and metastasis [
52,
53]. Interestingly, SNAI1, the transcription factor that represses E-cadherin expression (the marker of EMT induction), also enhances gene expression patterns that promote glucose uptake and glycolysis [
54]. Although we have not determined the expression of E-cadherin in SUM149 INV, it is possible, given the higher invasiveness and higher glycolytic rate, that SUM149 INV was also in the mesenchymal state, similar to our previous report about INV established from human pancreatic cell line, PANC-1, that showed higher ability than WCC, to invade and metastasize in mice, exhibited reduced E-cadherin expression with induction of pro-metastatic genes [
29].
Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.